Open Access<p>Inhibition of Skp2 Sensitizes Chronic Myeloid Leukemia Cells to Imatinib</p>
Author(s) -
Xiaowen Chen,
Zhenqi Huang,
Wei Wu,
Ruixiang Xia
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
ISSN - 1179-1322
DOI - 10.2147/cmar.s253367
Subject(s) - skp2 , cancer research , imatinib , pi3k/akt/mtor pathway , cell growth , protein kinase b , myeloid leukemia , k562 cells , medicine , cell cycle , ubiquitin ligase , apoptosis , tyrosine kinase , signal transduction , biology , ubiquitin , leukemia , immunology , microbiology and biotechnology , biochemistry , gene
Skp2 is an E3 ubiquitin ligase that plays an important role in modulating tumor progression. The mechanisms underlying Skp2 in the promotion of proliferation and its function in the primary resistance to tyrosine kinase inhibitors (TKIs) in human CML remain to be determined. This study aimed to investigate the function of Skp2 in CML progression as well as its effects on TKI sensitivity.